Trial Profile
A Phase 1b/2a Safety and Tolerability Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; ZEN 3694 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Zenith Epigenetics
- 12 Jul 2020 Results published in the Clinical Cancer Research
- 12 Jul 2020 Status changed to completed as per results published in the Clinical Cancer Research
- 23 Jul 2019 Planned End Date changed from 1 Jun 2019 to 1 Oct 2019.